ITTO991021A1 - Antagonisti ii del recettore ccr-3. - Google Patents

Antagonisti ii del recettore ccr-3.

Info

Publication number
ITTO991021A1
ITTO991021A1 IT1999TO001021A ITTO991021A ITTO991021A1 IT TO991021 A1 ITTO991021 A1 IT TO991021A1 IT 1999TO001021 A IT1999TO001021 A IT 1999TO001021A IT TO991021 A ITTO991021 A IT TO991021A IT TO991021 A1 ITTO991021 A1 IT TO991021A1
Authority
IT
Italy
Prior art keywords
ccr
receptor antagonists
antagonists
receptor
Prior art date
Application number
IT1999TO001021A
Other languages
English (en)
Inventor
Denis John Kertesz
David Bernard Smith
Donald Roy Hirschfeld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ITTO991021A0 publication Critical patent/ITTO991021A0/it
Publication of ITTO991021A1 publication Critical patent/ITTO991021A1/it
Application granted granted Critical
Publication of IT1308657B1 publication Critical patent/IT1308657B1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IT1999TO001021A 1998-11-20 1999-11-22 Antagonisti ii del recettore ccr-3. IT1308657B1 (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10929398P 1998-11-20 1998-11-20

Publications (3)

Publication Number Publication Date
ITTO991021A0 ITTO991021A0 (it) 1999-11-22
ITTO991021A1 true ITTO991021A1 (it) 2001-05-22
IT1308657B1 IT1308657B1 (it) 2002-01-09

Family

ID=22326896

Family Applications (1)

Application Number Title Priority Date Filing Date
IT1999TO001021A IT1308657B1 (it) 1998-11-20 1999-11-22 Antagonisti ii del recettore ccr-3.

Country Status (20)

Country Link
US (1) US6342509B1 (it)
EP (1) EP1131290B1 (it)
JP (1) JP3421323B2 (it)
KR (1) KR20010081034A (it)
CN (1) CN1326440A (it)
AR (1) AR029151A1 (it)
AT (1) ATE386720T1 (it)
AU (1) AU1774600A (it)
BR (1) BR9915735A (it)
CA (1) CA2351631A1 (it)
CO (1) CO5140118A1 (it)
DE (2) DE69938193D1 (it)
ES (1) ES2158813B1 (it)
FR (1) FR2786179B1 (it)
GB (1) GB2343894B (it)
IT (1) IT1308657B1 (it)
PE (1) PE20001401A1 (it)
TR (1) TR200101397T2 (it)
WO (1) WO2000031033A1 (it)
ZA (1) ZA200103940B (it)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60023878T2 (de) 1999-05-18 2006-07-20 Teijin Ltd. Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen
WO2001010439A1 (en) 1999-08-04 2001-02-15 Teijin Limited Cyclic amine ccr3 antagonists
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
CA2423251A1 (en) 2000-09-29 2002-04-04 Glaxo Group Limited Morpholin-acetamide derivatives for the treatment of inflammatory diseases
AU2002216107A1 (en) * 2000-12-19 2002-07-01 F. Hoffmann-La Roche Ag Substituted pyrrolidines as CCR-3 receptor antagonists
WO2002088111A1 (en) 2001-04-27 2002-11-07 Mitsubishi Pharma Corporation Novel benzylpiperidine compound
GB0114699D0 (en) 2001-06-15 2001-08-08 Novartis Ag Organic compounds
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
CN1753891A (zh) 2003-02-27 2006-03-29 霍夫曼-拉罗奇有限公司 Ccr－3受体拮抗剂
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
JP4710606B2 (ja) 2003-04-18 2011-06-29 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
SG131946A1 (en) * 2003-10-24 2007-05-28 Hoffmann La Roche Ccr3 receptor antagonists
SE0400208D0 (sv) * 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
IN2014CN03493A (it) 2004-09-08 2015-07-03 Mitsubishi Tanabe Pharma Corp
KR101231466B1 (ko) 2004-09-13 2013-02-07 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는약제
EP1889622A4 (en) 2005-05-31 2009-12-23 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
TW200734305A (en) * 2005-08-02 2007-09-16 Astrazeneca Ab New salt III
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200738635A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
ES2427989T3 (es) 2005-10-28 2013-11-05 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
JPWO2007105637A1 (ja) 2006-03-10 2009-07-30 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
DE102008020746A1 (de) * 2008-04-25 2009-10-29 Saltigo Gmbh Verfahren zur Herstellung von quarternären Salzen von Piperidyl Estern der Mandelsäure
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
KR101180174B1 (ko) * 2010-04-23 2012-09-05 동아제약주식회사 신규한 벤즈아미드 유도체
JP6392344B2 (ja) 2013-07-25 2018-09-19 ドン−ア エスティ カンパニー リミテッド ベンズアミド誘導体の製造方法、その製造に使用される新規な中間体及び該中間体の製造方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1574418A (en) * 1976-11-16 1980-09-03 Anphar Sa Piperidine derivatives
US4163784A (en) * 1978-03-09 1979-08-07 Pfizer Inc. Heterocyclylcarbonyl derivatives of urea, agents for dissolution of gallstones
DK159420C (da) 1983-03-09 1991-03-11 Ciba Geigy Ag N-(piperidinyl-alkyl)-carboxamider og salte deraf, farmaceutiske praeparater indeholdende disse forbindelser samt anvendelsen af forbindelserne til fremstilling af antipsykotiske farmaceutiske praeparater
US4579947A (en) 1983-06-16 1986-04-01 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted phenylalkylpiperazinylpropyl (ureas or thioureas) useful for treatment of immunological, inflammatory and allergic disorder
DK623586A (da) 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
US4857330A (en) 1986-04-17 1989-08-15 Alza Corporation Chlorpheniramine therapy
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
CA2005741C (en) 1988-12-26 1998-06-02 Hiroyoshi Hidaka Quinoline sulfonoamino compounds having vessel smooth muscle relaxation activity
FI97540C (fi) 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
JPH041128A (ja) 1990-03-07 1992-01-06 Ajinomoto Co Inc 抗不整脈薬
US5143923B1 (en) 1991-04-29 1993-11-02 Hoechst-Roussel Pharmaceuticals Incorporated Benzoisothiazole-and benzisoxazole-3-carboxamides
FR2677019B1 (fr) 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
US5438064A (en) * 1991-12-23 1995-08-01 American Home Products Corporation Derivatives of 4-anilinoquinoline-3-carboxamide as analgesic agents
FR2688219B1 (fr) 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
DK60893D0 (da) 1993-05-26 1993-05-26 Novo Nordisk As Piperidinderivater, deres fremstilling og anvendelse
WO1995000481A1 (en) 1993-06-23 1995-01-05 Merrell Dow Pharmaceuticals Inc. Piperidin-1-yl-2,2-dialkylpropanonearylsulfonamide derivatives
EP0661266A1 (en) 1993-12-27 1995-07-05 Toa Eiyo Ltd. Substituted cyclic amine compounds as 5HT2 antagonists
CA2517691A1 (en) 1994-08-19 1996-02-29 Abbott Laboratories Endothelin antagonists
JPH0977742A (ja) * 1995-09-12 1997-03-25 Kyorin Pharmaceut Co Ltd 新規なベンズアミド誘導体
GB9523526D0 (en) 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
CA2188485A1 (en) 1995-11-17 1997-05-18 Ronald J. Mattson Piperidinylethylamide derivatives as serotonergic agents
CA2197364A1 (en) 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
JP4150435B2 (ja) * 1996-04-18 2008-09-17 株式会社資生堂 アルキレンジアミン誘導体及び抗潰瘍剤、抗菌剤
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
AU3633997A (en) 1996-07-29 1998-02-20 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
US6136827A (en) 1997-07-25 2000-10-24 Merck & Co., Inc. Cyclic amine modulations of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AU2335699A (en) * 1998-01-21 1999-08-09 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
CN1158256C (zh) 1998-11-20 2004-07-21 霍夫曼-拉罗奇有限公司 吡咯烷衍生物-ccr-3受体拮抗剂
EP1156807A4 (en) 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS

Also Published As

Publication number Publication date
GB2343894B (en) 2001-07-25
TR200101397T2 (tr) 2001-11-21
GB2343894A (en) 2000-05-24
AR029151A1 (es) 2003-06-18
GB9927228D0 (en) 2000-01-12
DE69938193D1 (de) 2008-04-03
EP1131290A1 (en) 2001-09-12
KR20010081034A (ko) 2001-08-25
US6342509B1 (en) 2002-01-29
CN1326440A (zh) 2001-12-12
WO2000031033A1 (en) 2000-06-02
PE20001401A1 (es) 2000-12-15
ATE386720T1 (de) 2008-03-15
ES2158813B1 (es) 2002-03-16
AU1774600A (en) 2000-06-13
BR9915735A (pt) 2001-09-04
ZA200103940B (en) 2002-08-15
FR2786179B1 (fr) 2001-08-10
JP3421323B2 (ja) 2003-06-30
CO5140118A1 (es) 2002-03-22
EP1131290B1 (en) 2008-02-20
ES2158813A1 (es) 2001-09-01
CA2351631A1 (en) 2000-06-02
ITTO991021A0 (it) 1999-11-22
DE19955793A1 (de) 2000-05-25
IT1308657B1 (it) 2002-01-09
JP2002530375A (ja) 2002-09-17
FR2786179A1 (fr) 2000-05-26

Similar Documents

Publication Publication Date Title
IT1307900B1 (it) Antagonisti iii del recettore ccr-3.
IT1307062B1 (it) Antagonisti iii del recettore ccr-3.
IT1308657B1 (it) Antagonisti ii del recettore ccr-3.
TR199801594A3 (tr) CCR-3 reseptör antagonistleri.
DZ2320A1 (fr) Antagonistes de récepteurs de vitronectine.
CY2010003I1 (el) Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
ZA975671B (en) IL-8 receptor antagonists.
ZA200204395B (en) Selective neurokinin antagonists.
ZA977301B (en) IL-8 receptor antagonists.
ZA9810685B (en) Thrombin receptor antagonists.
TR199501389A2 (tr) Adesyon reseptörü antagonistleri (karsitlari).
ID24162A (id) Antagonis-antagonis reseptor vitronektin
NO20016053L (no) IL-8 reseptor-antagonister
ZA200110127B (en) Substituted benzimidazole.
NO20016052D0 (no) IL-8-reseptor-antagonister
MXPA01012165A (es) Antagonistas ccr3 del receptor de quimiocina.
DK1180028T3 (da) IL-8-receptorantagonister
ZA200109627B (en) IL-8 receptor antagonists.
ZA200201780B (en) Vitronectin receptor antagonists.
ZA986551B (en) Endothelin receptor antagonists.
TR199601082A3 (tr) Entegrin reseptör antagonistleri.
DK1131291T3 (da) 4-aroyl-piperidin-CCR-3-receptorantagonister III
ZA200110203B (en) IL-8 receptor antagonists.
ZA200110205B (en) IL-8 receptor antagonists.
MXPA03005581A (es) Pirrolidinas substituidas como antagonistas del receptor ccr-3.